


PRODUCT INFORMATION



Mitapivat

Item No. 43908

CAS Registry No.: 1260075-17-9
Formal Name: N-[4-[[4-(cyclopropylmethyl)-1-piperazinyl]carbonyl]phenyl]-8-quinolinesulfonamide
Synonym: AG-348
MF: C₂₄H₂₆N₄O₃S
FW: 450.6
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mitapivat is supplied as a solid. A stock solution may be made by dissolving the mitapivat in the solvent of choice, which should be purged with an inert gas. Mitapivat is slightly soluble (0.1-1 mg/ml) in DMSO.

Description

Mitapivat is an allosteric activator of erythrocyte pyruvate kinase (PKR).¹ It increases PKR activity and ATP levels in red blood cells isolated from patients with pyruvate kinase deficiency when used at a concentration of 10 μM. Mitapivat increases hematocrit and hemoglobin levels, decreases osmotic fragility, and reduces splenic erythrophagocytosis in a model of hereditary spherocytosis using protein 4.2 knockout (4.2^{-/-}) mice.² Formulations containing mitapivat have been used in the treatment of hemolytic anemia in patients with pyruvate kinase deficiency.

References

1. Rab, M.A.E., Van Oirschot, B.A., Kosinski, P.A., *et al.* AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. *Haematologica* **106(1)**, 238-249 (2021).
2. Matte, A., Wilson, A.B., Gevi, F., *et al.* Mitapivat reprograms the RBC metabolome and improves anemia in a mouse model of hereditary spherocytosis. *JCI Insight* **8(20)**, e172656 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/09/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM